AACR Translational Cancer Research for Basic Scientists Workshop
November 8-13, 2015
Omni Parker House Hotel • Boston, Massachusetts

Chairpersons:
Tom Curran, PhD, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts

Program Committee:
Peter C. Adamson, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Suzanne J. Baker, St. Jude’s Research Hospital, Memphis, Tennessee
Edward J. Benz, Dana-Farber Cancer Institute, Boston, Massachusetts
Alexis Borisy, Third Rock Ventures, LLC, Boston, Massachusetts
Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Susan Band Horwitz, Albert Einstein College of Medicine, Bronx, New York
Neal I. Lindeman, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
Richard M. Marais, PhD, Cancer Research UK Manchester Institute, Manchester, England
George C. Prendergast, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania
Mark E. Robson, Memorial Sloan Kettering Cancer Center, New York, New York

Sunday, November 8, 2015

3:00-7:30 p.m. Registration

5:00-6:00 p.m. Welcome and Introductions:
A Conversation and Open Forum with the Course Directors

Tom Curran, PhD
The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

George D. Demetri, MD
Dana-Farber Cancer Institute, Boston, Massachusetts

Pasi A. Jänne, MD, PhD
Dana-Farber Cancer Institute, Boston, Massachusetts

6:00-6:30 p.m. Pre-Assessment

6:30-7:30 p.m. Opening Keynote Presentation

Translational research in the molecular era
Craig B. Thompson, MD
Memorial Sloan Kettering Cancer Center, New York, New York

7:30-9:30 p.m. Opening Reception and Dinner
7:00-8:00 a.m.  Continental Breakfast

8:00-11:30 a.m.  Introduction to Cancer Medicine and Diagnostics

8:00-8:45 a.m.
Overview: An introduction to clinical cancer medicine
George D. Demetri, MD
Dana-Farber Cancer Institute, Boston, Massachusetts

8:45-9:15 a.m.
Overview of pathology and molecular tools in diagnostics
Neal I. Lindeman, MD
Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

9:15-9:45 a.m.
Cancer imaging
Lawrence H. Schwartz, MD
Columbia University Medical Center, New York, New York

9:45-11:15 a.m.
Biomarkers and molecular diagnostics: The problem of patient selection
Maureen Cronin, PhD
Celgene Corporation, San Francisco, California

10:15-11:15 a.m.
EGFR mutant lung cancer: A model for personalized cancer therapy
Pasi A. Jänne, MD, PhD
Dana-Farber Cancer Institute, Boston, Massachusetts

11:30 a.m.-12:15 p.m.  Buffet Lunch

12:15-5:15 p.m.  Offsite Laboratory Visits
Dana-Farber Cancer Institute
*Transportation will be provided.

12:15-1:00 p.m.
Travel time to observational visits
1:00-4:15 p.m.
Offsite Observational Visits
- Surgical Pathology Laboratory tour and discussion
- Diagnostic Radiology Laboratory tour and discussion
*Workshop attendees visit both laboratories during the time allotted.

Schedule:
1:00-2:30 Session 1
2:30-2:45 Switch between labs and brief break
2:45-4:15 Session 2

4:15-5:15 p.m.
Travel time back to hotel

5:15-6:15 p.m.
Group Buffet Dinner

6:15-7:00 p.m.
The Cancer Genome Atlas
Chris Sander, Memorial Sloan Kettering Cancer Center, New York, New York

7:00-8:00 p.m.
Panel Discussion: Getting Started in Translational Research
- Tom Curran, PhD, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
- Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
- Richard M. Marais, PhD, Cancer Research UK Manchester Institute, Manchester, England
- Keith T. Flaherty, MD, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

TUESDAY, NOVEMBER 10, 2015
Chairperson of the Day: Mark E. Robson, Memorial Sloan Kettering Cancer Center, New York, New York

7:00-8:00 a.m.
Continental Breakfast

8:00-8:30 a.m.
Keynote Presentation
Perspective on the future of cancer research from the head of a cancer center
Edward J. Benz, Jr., MD
Dana-Farber Cancer Institute, Boston, Massachusetts

8:30-10:30 a.m.
The Environment of Clinical Investigations

8:30-9:05 a.m.
Clinical research: An overview
Peter C. Adamson, MD
The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
9:05-9:40 a.m.  
**Human subjects considerations in designing translational research projects**  
Mark E. Robson, MD  
Memorial Sloan Kettering Cancer Center, New York, New York

9:40-10:15 a.m.  
**Reviewing, approving, and managing research involving human subjects**  
Michele Russell-Einhorn, JD  
Dana-Farber Cancer Institute, Boston, Massachusetts

10:15-10:30 a.m.  
**Panel discussion and questions: Clinical research**

10:45 a.m.-3:00 p.m.  
**Offsite IRB Observational Visit**  
Dana-Farber Cancer Institute  
*Transportation will be provided.*

Participants observe a live Institutional Review Board (IRB) session in order to gain insights into issues of protection of human subjects that are at the heart of translational research. One to two weeks beforehand, application titles will be shared with the attendees if possible.

10:45-11:30 a.m.  
Board bus and travel to IRB session/Pick up box lunches

11:30 a.m.-12:00 p.m.  
**Lunch/Overview of IRB**  
George D. Demetri, MD  
Dana-Farber Cancer Institute, Boston, Massachusetts

12:00-2:00 p.m.  
**Observation of Live IRB Session**

2:00-3:00 p.m.  
**Panel Discussion and Questions on Live IRB Session**

3:00-4:00 p.m.  
Travel time back to hotel

4:00-5:30 p.m.  
**One-on-One Meetings ("Office Hours")**  
- Chris Bowden, Agios Pharmaceuticals, Cambridge, Massachusetts  
- Peter Ho, Epizyme, Cambridge, Massachusetts  
- Susan Band Horwitz, Albert Einstein Medical College, Bronx, New York  
- Donna S. Neuberg, Dana-Farber Cancer Institute, Boston, Massachusetts  
- Patrick Ott, Dana-Farber Cancer Institute, Boston, Massachusetts  
- George C. Prendergast, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania  
- Mark E. Robson, Memorial Sloan Kettering Cancer Center, New York, New York
* Sign-up sheets to schedule a time to speak with particular faculty members will be available at the Registration Desk.
**Note that the last two appointments for this will overlap with dinner. Those who do not have a One-on-One Meeting scheduled should proceed to the meal room for dinner beginning at 5:00 p.m.

5:00-6:00 p.m.  Group Buffet Dinner

6:00-7:00 p.m.  Panel Discussion on Entrepreneurship in Translational Research

Alexis Borisy, Third Rock Ventures, LLC, Boston, Massachusetts
George C. Prendergast, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania
Charles J. Link Jr., NewLink Genetics Corp., Ames, Iowa

7:00-8:30 p.m.  Special Seminar and Group Discussion: Unleashing the Power of Immune system - Focus on Translational Immunology

7:00-7:30 p.m.
LAB/TRANSLATIONAL:
PD-1 cancer immunotherapy
Gordon J. Freeman, PhD
Dana-Farber Cancer Institute, Boston, Massachusetts

7:30-8:00 p.m.
CLINICAL:
PD-1/PD-L1 inhibition in melanoma and other cancers
Patrick Ott, MD
Dana-Farber Cancer Institute, Boston, Massachusetts

8:00-8:30 p.m.
Group Discussion and Q&A

WEDNESDAY, NOVEMBER 11, 2015

Chairperson of the Day: George C. Prendergast, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania

6:45-7:30 a.m.  Continental Breakfast
*It is important that we remain on schedule to arrive at the clinics on time. Please feel free to bring food and drink into the session room if needed.

7:30-8:00 a.m.  Orientation/Questions for Cancer Patient Clinic Visits
George D. Demetri, MD and Pasi A. Jänne, MD, PhD
Dana-Farber Cancer Institute, Boston, Massachusetts

8:00 a.m.-12:00 p.m.  Offsite Patient Clinic Visits
Dana-Farber Cancer Institute
Massachusetts General Hospital
8:00-9:30 a.m.  
Board bus, travel to patient clinics, and onsite preparation

9:30-11:30 a.m.  
*Interactive Observational Visits to Cancer Patient Clinics*

11:30 a.m.-12:00 p.m.  
Travel time

12:00-1:00 p.m.  
*Buffet Lunch*

1:00-4:15 p.m.  
*The Research & Development Process*

1:00-1:45 p.m.  
*Story of Taxol*  
**Susan Band Horwitz, PhD**  
Albert Einstein Medical College, Bronx, New York

1:45-2:15 p.m.  
*Development of mutant IDH2 inhibitors: From concept to patients*  
**Chris Bowden, MD**  
Agios Pharmaceuticals, Cambridge, Massachusetts

2:15-2:45 p.m.  
*Acapreneurial research: A more inventive and impactful environment for biomedical research*  
**George C. Prendergast, PhD**  
Lankenau Institute for Medical Research, Wynnewood, Pennsylvania

2:45-3:15 p.m.  
*Break*

3:15-3:45 p.m.  
*The role of variability*  
**Donna S. Neuberg, DSc**  
Dana-Farber Cancer Institute, Boston, Massachusetts

3:45-4:15 p.m.  
*Panel discussion and questions: Research and development*

4:15-5:45 p.m.  
*Interactive Lab and Demo-cBioPortal: Cancer Genomics and Translational Research*  
*The cBioPortal for cancer genomics*  
**Nikolaus Schultz, PhD**, Memorial Sloan Kettering Cancer Center, New York, New York  
**Ethan Cerami, PhD**, Dana-Farber Cancer Institute, Boston, Massachusetts

5:45-6:30 p.m.  
*Group Dinner*
Small Group Discussion Sessions with Clinician and Patient
Each small group consists of a clinician, a patient, and approximately 10-15 workshop attendees. This provides a comfortable environment and encourages interaction. We ask doctors to share their perspectives as clinicians and researchers; and patients to speak about whatever they feel most comfortable sharing regarding their experiences as patients/clinical trial participants.

THURSDAY, NOVEMBER 12, 2015
Chairperson of the Day: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts

6:45-7:30 a.m. Continental Breakfast
*It is important that we remain on schedule to arrive at the clinics on time. Please feel free to bring food and drink into the session room if needed.

7:30-8:00 a.m. Orientation/Questions for Cancer Patient Clinic Visits
George D. Demetri, MD and Pasi A. Jänne, MD, PhD
Dana-Farber Cancer Institute, Boston, Massachusetts

8:00 a.m.-12:00 p.m. Offsite Patient Clinic Visits
Dana-Farber Cancer Institute
Massachusetts General Hospital

8:00-9:30 a.m. Board bus, travel to patient clinics, and onsite preparation

9:30-11:30 a.m. Interactive Observational Visits to Cancer Patient Clinics

11:30 a.m.-12:00 p.m. Travel time

12:00-1:00 p.m. Buffet Lunch

1:00-5:00 p.m. Targeted Medicine

1:00-1:30 p.m. TBD
Geoffrey R. Oxnard, MD
Dana-Farber Cancer Institute, Boston, Massachusetts

1:30-2:00 p.m. Heterogeneity in breast cancer: Relevance and therapeutic implications
Kornelia Polyak, MD, PhD
Dana-Farber Cancer Institute, Boston, Massachusetts

2:00-2:30 p.m. Break
2:30-3:15 p.m.
Addressing clonal heterogeneity with personalized neoantigen-targeting vaccines
Catherine J. Wu, MD
Dana-Farber Cancer Institute, Boston, Massachusetts

3:15-3:45 p.m.
Targeting epigenetic therapies: Fitting EZH2 inhibitors into pockets of disease
Peter Ho, MD, PhD
Epizyme, Cambridge, Massachusetts

3:45-4:15 p.m.
Developing prototype drugs in academia: EGFR, Cdk7, Her3 and RAS
Nathanael S. Gray, PhD
Dana-Farber Cancer Institute, Boston, Massachusetts

4:15-5:00 p.m.
Panel Discussion and Questions: Targeted Medicine

5:00-
Free Evening/Dinner on own

FRIDAY, NOVEMBER 13, 2015
Chairperson of the Day: Joshua D. Schiffman, University of Utah, Salt Lake City, Utah

7:00-8:00 a.m.
Continental Breakfast

8:00-10:15 a.m.
Translating Differently

8:00-8:30 a.m.
CRISPR and new technologies
George M. Church, Harvard Medical School, Boston, Massachusetts

8:30-9:00 a.m.
Remodeling the remodelers: BAF complex structure and function in human cancers
Cigall Kadoch, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts

9:00-9:30 a.m.
Molecular epidemiology and translational genomics: Understanding who gets cancer and what we can do about it
Joshua D. Schiffman, MD
University of Utah, Salt Lake City, Utah

9:30-10:15 a.m.
Panel Discussion
10:15-10:30 a.m.  Closing Discussion Forum and Observations with the Course Directors

Tom Curran, PhD  
The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

George D. Demetri, MD  
Dana-Farber Cancer Institute, Boston, Massachusetts

10:30-11:30 a.m.  Post-Assessment and Evaluation

11:45 a.m.  Attendee Departure  
Collection of Evaluations

*Please turn in your Post-Assessment test and Evaluation to receive your workshop certificate